Group 1 - Leap Motor announced the completion of a domestic stock issuance, raising a total of 2.6 billion yuan, with funds aimed at supporting core technology R&D and enhancing vehicle performance and smart features [2] - Xizhi Technology completed a C-round financing exceeding 1.5 billion yuan, with participation from notable investors, aiming to accelerate the commercialization of photonic chips in computing centers [3] - Jinbei Automotive plans to invest 240 million yuan as a limited partner in the Shenyang Automotive Industry Investment Fund, which has a total subscription amount of 800 million yuan [4] Group 2 - Anthropic raised 13 billion USD in its F-round financing, achieving a post-money valuation of 183 billion USD, with plans to expand enterprise customer adoption and enhance safety research [5] - Figure Technologies plans to raise up to 526.32 million USD through an IPO, with a proposed share price range of 18 to 20 USD [6] - Black Rock Coffee Bar aims for an IPO seeking a valuation of up to 860.7 million USD, marking a rare consumer sector IPO amid a tech-driven market recovery [8] Group 3 - The Jinan Zhongying Industrial Development Semiconductor AI Equity Investment Partnership was established with a capital contribution of 1 billion yuan, focusing on private equity investments [9] - The Honghui Yuyin Fund, a smart medical equipment fund, was launched in Banan District with a scale of 500 million yuan, targeting investments in the healthcare sector [10] - Caitong Capital's Caitong Qihang Fund completed an exclusive investment in Wase Technology, focusing on global demand for audio-visual technology solutions [11] Group 4 - The Beijing Agricultural Industry Investment Fund was officially launched with a total scale of 500 million yuan, expected to generate 600 million yuan in new output and create 1.5 billion yuan in tax revenue [12]

36氪获悉，近期，睿健毅联医药科技（成都）有限公司（下称"睿健医药"）已完成一笔新的B+轮次融 资。本轮融资由北极光创投、创景资本、元希海河等机构共同投资，易凯资本任独家财务顾问。 本次募集资金将用于加速推进公司旗下帕金森病治疗产品NouvNeu001/NouvNeu003、眼科治疗产品 NouvSight001的临床研发，以及团队建设和产业化能力。 睿健医药成立于2017年，专注于小分子化学转录调控诱导多能干细胞（iPSC）产品开发。今年4月，睿 健医药就曾官宣一笔过亿元B+轮融资。公司的B轮次融资金额累计已超过3亿元。 睿健医药的核心产品NouvNeu001是一款化学诱导的功能型人源多巴胺能神经元前体细胞。此前完成 B+轮融资时，睿健医药创始人、CEO魏君曾对36氪介绍，该产品已启动多中心II期临床试验。此前的I 期临床中，NouvNeu001在移植15个月后的患者中"展现出了良好的安全性和耐受性"；同时，PET影像 分析也显示，随着移植时间增加，细胞在患者体内实现无免疫抑制剂状况下的长期存续。 创始人及投资人观点： 睿健医药创始人、CEO魏君表示，感谢新老投资人对睿健的信任和持续支持，也感谢易凯资本和睿 ...

Core Viewpoint - RuiJian Pharmaceutical has recently completed over 100 million yuan in Series B+ financing, led by Fengchuan Capital, to accelerate clinical trials and product development for its core pipeline targeting Parkinson's disease [4][5]. Financing and Growth - The company has raised over 200 million yuan in total from two rounds of Series B financing [5]. - RuiJian Pharmaceutical focuses on the development of small molecule chemical transcription regulation-induced pluripotent stem cell (iPSC) products since its establishment in 2017 [5]. Product Development and Clinical Trials - The core product NouvNeu001, aimed at treating Parkinson's disease, has recently entered Phase II clinical trials [5][6]. - Initial Phase I clinical results showed significant clinical improvement in motor functions and non-motor symptoms in patients after six months of cell transplantation [7]. - The product has demonstrated long-term efficacy, with some patients showing stable improvements in behavior and mobility beyond 60 weeks post-treatment [7]. Future Prospects and Regulatory Approvals - RuiJian Pharmaceutical is also developing NouvNeu003, targeting early-onset Parkinson's patients under 50, which has received approval for Phase I clinical trials [8]. - The company has made progress in overseas clinical research, with NouvNeu001's IND application approved in the U.S. and expected to start Phase I trials soon [8]. Market Position and Investor Insights - The founder and CEO, Dr. Wei Jun, emphasized the company's commitment to addressing clinical needs and providing innovative therapies that can potentially reverse disease progression [9]. - Investors express confidence in RuiJian Pharmaceutical's technology and its potential to become a leading player in the iPSC field, highlighting the significant social and commercial value of its products [10].